SillaJen Presents Preclinical Results of Anticancer Platform 'SJ-600' at US International Conference

Shinilgen announced on the 16th that it successfully concluded the presentation of preclinical research results on its oncolytic virus platform 'SJ-600' series at the international conference CRD (Cancer Research & Drug Development) held in Boston, USA.

SillaJen CI. [Image provided by SillaJen]

This presentation was conducted following an official invitation from the conference organizers to Shinilgen. Accordingly, the chief researcher of the institute, who is the developer of SJ-600, delivered the invited lecture on the 14th (local time).

At this conference, Shinilgen presented the excellence of the SJ-600 series, which is being developed as the next-generation oncolytic virus platform. They emphasized that the ability to evade neutralizing antibody responses upon repeated administration attracted significant attention. This effectively overcomes the limitations of existing oncolytic viruses, which were practically unsuitable for periodic administration, making it applicable even to patients who have developed antibodies against the virus, according to Shinilgen.

The 'SJ-607' disclosed through this presentation expresses the complement regulatory protein CD55 on the viral envelope, enabling the oncolytic virus to survive stably in the bloodstream. It can be administered systemically via intravenous injection, allowing direct drug delivery not only to solid tumors but also to metastatic cancers. The company highlighted that even with a smaller amount administered intravenously compared to direct intratumoral injection, SJ-607 demonstrates superior anticancer efficacy, suggesting its potential application in treating deeply located tumors or metastatic cancers through intravenous administration.

Earlier in January, the SJ-600 series published its preclinical results in a paper in the official journal of the Society for Immunotherapy of Cancer (SITC), the Journal for ImmunoTherapy of Cancer (JITC). Following the journal publication, CRD officially expressed its invitation to Shinilgen.

A Shinilgen representative stated, "The fact that we received a direct invitation from an international conference indicates the high expectations in the academic community for SJ-600," adding, "We will pursue global licensing out once additional experiments are completed."

Meanwhile, CRD is an international conference organized by the nonprofit organization United Scientific Group, dedicated to advancing cancer research, and has been held in rotation across the United States and Europe since 2016.

This content was produced with the assistance of AI translation services.